Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant

Clinical Pharmacology and Therapeutics

Volumn 78, Issue 3, 2005, Pages 298-308

  McDonald, George B ^a   McCune, Jeannine S ^a   Batchelder, Ami ^a   Cole, Scott ^a   Phillips, Brian ^a   Ren, Aaron G ^a   Vicini, Paolo ^a   Witherspoon, Robert ^a   Kalhorn, Thomas F ^a   Slattery, John T ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; MESNA; METHOTREXATE; URSODEOXYCHOLIC ACID;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CELL TRANSPLANTATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG METABOLISM; FEASIBILITY STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; HUMAN; INFECTION; LIVER DISEASE; LIVER TOXICITY; MALE; MATHEMATICAL ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; BAYES THEOREM; BLOOD PLATELETS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DRUG DELIVERY SYSTEMS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS, TOXIC; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEUTROPHILS; PHOSPHORAMIDE MUSTARDS;

EID: 24344447604     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.05.005     Document Type: Article

References (43)

1. H. Gurney Dose calculation of anticancer drugs a review of the current practice and introduction of an alternative J Clin Oncol 14 1996 2590 2611
2. S.D. Baker, J. Verweij, E.K. Rowinsky, R.C. Donehower, J.H. Schellens, L.B. Grochow Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001 J Natl Cancer Inst 94 2002 1883 1888
3. G.B. McDonald, J.T. Slattery, M.E. Bouvier, S. Ren, A.L. Batchelder, T.F. Kalhorn Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation Blood 101 2003 2043 2048
4. J.S. McCune, J.P. Gibbs, J.T. Slattery Plasma concentration monitoring of busulfan does it improve clinical outcome? Clin Pharmacokinet 39 2000 155 165
5. A.H. Calvert, D.R. Newell, L.A. Gumbrell, S. O'Reilly, M. Burnell, F.E. Boxall Carboplatin dosage prospective evaluation of a simple formula based on renal function J Clin Oncol 7 1989 1748 1756
6. W.E. Evans, M.V. Relling, J.H. Rodman, W.R. Crom, J.M. Boyett, C.H. Pui Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia N Engl J Med 338 1998 499 505
7. J.T. Slattery, J.E. Sanders, C.D. Buckner, R.L. Schaffer, K.W. Lambert, F.P. Langer Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics Bone Marrow Transplant 16 1995 31 42
8. J.P. Radich, T. Gooley, W. Bensinger, T. Chauncey, R. Clift, M. Flowers HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen Blood 102 2003 31 35
9. W.L. Furman, S.D. Baker, C.B. Pratt, G.K. Rivera, W.E. Evans, C.F. Stewart Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia J Clin Oncol 14 1996 1504 1511
10. M.E. De Jonge, H.J.G.D. van den Bongard, A.D.R. Huitema, R.A.A. Mathot, H. Rosing, P. Baas Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer Clin Cancer Res 10 2004 2237 2244
11. M.E. de Jonge, A.D. Huitema, A.C. Tukker, S.M. van Dam, S. Rodenhuis, J.H. Beijnen Accuracy, feasibility, and clinical impact of prospective bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy Clin Cancer Res 11 2005 273 283
12. G.B. McDonald, M.S. Hinds, L.B. Fisher, H.G. Schoch, J.L. Wolford, M. Banaji Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation a cohort study of 355 patients Ann Intern Med 118 1993 255 267
13. E. Carreras, H. Bertz, W. Arcese, J.P. Vernant, J.F. Thomas, H. Hagglund Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation a prospective cohort study of the European group for blood and marrow transplantation Blood 92 1998 3599 3604
14. M. Colvin, J.E. Russo, J. Hilton, D.M. Dulik, C. Fenselau Enzymatic mechanisms of resistance to alkylating agents in tumor cells and normal tissues Adv Enzyme Regul 27 1988 211 221
15. T.A. Connors, P.J. Cox, P.B. Farmer, A.B. Foster, M. Jarman Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide Biochem Pharmacol 23 1974 115 129
16. R.F. Struck, M.C. Kirk, M.H. Witt, W.R.J. Laster Isolation and mass spectral identification of blood metabolites of cyclophosphamide evidence for phosphoramide mustard as the biologically active metabolite Biomed Mass Spectrom 2 1975 46 52
17. S. Ren, J.-S. Yang, T.F. Kalhorn, J.T. Slattery Oxidation of cyclophosphamide to 4-hydroxycyclophosphomide and deschloroethylcyclophosphamide in human liver microsomes Cancer Res 57 1997 4229 4235
18. R.F. Struck, M.C. Kirk, L.B. Mellett, S. el Dareer, D.L. Hill Urinary metabolites of the antitumor agent cyclophosphamide Mol Pharmacol 7 1971 519 529
19. N.E. Sladek Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo Cancer Res 33 1973 1150 1158
20. C.H. Kwon, R.F. Borch, J. Engel, U. Niemeyer Activation mechanisms of mafosfamide and the role of thiols in cyclophosphamide metabolism J Med Chem 30 1987 395 399
21. H.A. Dirven, B. van Ommen, P.J. van Bladeren Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione Cancer Res 54 1994 6215 6220
22. H.A. Dirven, J.C. Venekamp, B. van Ommen, P.J. van Bladeren The interaction of glutathione with 4-hydroxycyclophosphamide and phosphoramide mustard, studied by 31P nuclear magnetic resonance spectroscopy Chem Biol Interact 93 1994 185 196
23. R. Qiu, T.F. Kalhorn, J.T. Slattery ABCC2-mediated biliary transport of 4-glutathionylcyclophosphamide and its contribution to elimination of 4-hydroxycyclophosphamide in rat J Pharmacol Exp Ther 308 2004 1204 1212
24. E. Petersdorf, C. Anasetti, P.J. Martin, T. Gooley, J. Radich, A. Malkki Limits of HLA mismatching in unrelated hematopoietic cell transplantation Blood 104 2004 2976 2980
25. T. Ruutu, B. Eriksson, K. Remes, E. Juvonen, L. Volin, M. Remberger Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation Blood 100 2002 1977 1983
26. J.T. Slattery, T.F. Kalhorn, G.B. McDonald, K. Lambert, C.D. Buckner, W.I. Bensinger Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients J Clin Oncol 14 1996 1484 1494
27. T.F. Kalhorn, S. Ren, W.N. Howald, R.F. Lawrence, J.T. Slattery Analysis of cyclophosphamide and five metabolites from human plasma using liquid chromatography-mass spectrometry and gas chromatography-nitrogen-phosphorus detection J Chromatogr B Biomed Sci Appl 732 1999 287 298
28. L.D. Deleve, H.M. Shulman, G.B. McDonald Toxic injury to hepatic sinusoids sinusoidal obstruction syndrome (veno-occlusive disease) Semin Liver Dis 22 2002 27 41
29. R. Qiu, A. Yao, P. Vicini, G.B. McDonald, A.L. Batchelder, M.E. Bouvier Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation prediction of exposure to the cyclophosphamide metabolite carboxyethylphosphoramide mustard Clin Pharmacol Ther 76 2004 270 280
30. L.B. Sheiner, S.L. Beal Some suggestions for measuring predictive performance J Pharmacokinet Biopharm 9 1981 503 512
31. R. Storb, R.B. Epstein, R.H. Rudolph, E.D. Thomas Allogeneic canine bone marrow transplantation following cyclophosphamide Transplantation 7 1969 378 386
32. R. Storb, C.D. Buckner, L.A. Dillingham, E.D. Thomas Cyclophosphamide regimens in rhesus monkey with and without marrow infusion Cancer Res 30 1970 2195 2203
33. E.D. Thomas, R. Storb, A. Fefer, S.J. Slichter, J.I. Bryant, C.D. Buckner Aplastic anaemia treated by marrow transplantation Lancet 1 1972 284 289
34. G.W. Santos, L.L. Sensenbrenner, P.J. Burke, M. Colvin, A.H. Owens Jr, W.B. Bias Marrow transplantation in man following cyclophosphamide Transplant Proc 3 1971 400 404
35. E.D. Thomas, C.D. Buckner, R.H. Rudolph, A. Fefer, R. Storb, P.E. Neiman Allogeneic marrow grafting for hematologic malignancy using HL-A matched donor-recipient sibling pairs Blood 38 1971 267 287
36. E.D. Thomas Bone marrow transplantation R.A. Good F.H. Bach Clinical immunobiology Vol. 2 1974 Academic Press New York 1 32
37. E.D. Thomas, N. Fluornoy, C.D. Buckner, R.A. Clift, A. Fefer, P.E. Neiman Cure of leukemia by marrow transplantation Leuk Res 1 1977 67 70
38. L.D. DeLeve, X.D. Wang, M.M. Huybrechts Cellular target of cyclophosphamide toxicity in the murine liver-role of glutathione and site of metabolic activation Hepatology 24 1996 830 837
39. V.I. Avramis, S. Sencer, A.P. Periclou, H. Sather, B.C. Bostrom, L.J. Cohen A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia a Children's Cancer Group study Blood 99 2002 1986 1994
40. M. Sandstrom, H. Lindman, P. Nygren, E. Lidbrink, J. Bergh, M.O. Karlsson Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients J Clin Oncol 23 2005 413 421
41. H. Minami A point, a line, or an area? Which is the most important in the pharmacological analysis of cancer chemotherapy? J Clin Oncol 23 2005 405 406
42. F.J. Giles, A.T. Stopeck, L.R. Silverman, J.E. Lancet, M.A. Cooper, A.L. Hannah SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes Blood 102 2003 795 801
43. A.D. Huitema, M. Spaander, R.A. Mathjt, M.M. Tibben, M.J. Holtkamp, J.H. Beijnen Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin Ann Oncol 13 2002 374 384